Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration-Reference-Cited by-同舟云学术

Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration

Published:2023-01-06 Issue:2 Volume:58 Page:125-133
ISSN:0735-0414
Container-title:Alcohol and Alcoholism
language:en
Short-container-title:

Author:

Guiraud Julien¹²^ORCID,Addolorato Giovanni³⁴^ORCID,Aubin Henri-Jean⁵⁶,Bachelot Sylvie⁷,Batel Philippe⁸,de Bejczy Andrea⁹,Benyamina Amine⁶,Caputo Fabio¹⁰¹¹,Couderc Monique¹²^ORCID,Dematteis Maurice¹³,Goudriaan Anna E¹¹⁴,Gual Antoni¹⁵,Lecoustey Sylvie⁷,Lesch Otto-Michael¹⁶,Maremmani Icro¹⁷,Nutt David J¹⁸,Paille François¹⁹,Perney Pascal²⁰,Rehm Jürgen²¹^ORCID,Rolland Benjamin²²,Scherrer Bruno²³,Simon Nicolas²⁴,Söderpalm Bo⁹,Somaini Lorenzo²⁵,Sommer Wolfgang H²⁶²⁷,Spanagel Rainer²⁶,Walter Henriette¹⁶,van den Brink Wim¹

Affiliation:

1. Amsterdam UMC, Location Academic Medical Center, University of Amsterdam , Department of Psychiatry, Amsterdam Neuroscience, Meibergdreef 5, 1105AZ Amsterdam , The Netherlands

2. Vergio, 31 rue Fernand Pelloutier , 92110 Clichy , France

3. Internal Medicine and Alcohol Related Disease Unit, Department of Medical and Surgical Sciences, Columbus-Gemelli Hospital, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Rome , Rome, 00168 , Italy

4. CEMAD Digestive Disease Center, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Catholic University of Rome , Rome, 00168 , Italy

5. French Institute of Health and Medical Research (Inserm), Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Universite Paris-Saclay , 94807, Villejuif , France

6. Addiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University , 94804, Villejuif , France

7. D&A Pharma , 7 rue d’Aguesseau, 75008 Paris , France

8. Addiction Unit of Charente, Camille Claudel Hospital , 16400 La Couronne , France

9. Section of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg , 41328, Gothenburg , Sweden

10. Department of Internal Medicine, SS. Annunziata Hospital, University of Ferrara , 44042, Cento (Ferrara) , Italy

11. Centre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara , 44042, Cento (Ferrara) , Italy

12. Petry Medical Consulting , 92150, Suresnes , France

13. Grenoble Alpes University, Faculty of Medicine and Grenoble-Alpes University Hospital , Department of Pharmacology and Addiction Medicine, 38043 Grenoble , France

14. Arkin, Dept. of Research and Quality of Care, Amsterdam Public Health Research Institute , 1033 NN Amsterdam , The Netherlands

15. Emeritus Researcher, GRAC (Addictions Research Group), IDIBAPS , 08036, Barcelona , Spain

16. University Clinic of Psychiatry and Psychotherapy, Department of Social Psychiatry, Medical University of Vienna , 1090, Vienna , Austria

17. Department of Neurosciences, Santa Chiara University Hospital, University of Pisa , 56100, Pisa , Italy

18. Centre for Neuropsychopharmacology, Imperial College London , W12 0NN, London , United Kingdom

19. Department of Addiction Treatment, University Hospital , 54500, Vandoeuvre-lès-Nancy , France

20. Department of Addiction Medicine, CHU Nîmes; French Institute of Health and Medical Research (Inserm), Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Universite Paris-Saclay , Villejuif, 94807 , France

21. Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, M5S2S1, Canada; Dalla Lana School of Public Health & Department of Psychiatry, University of Toronto, Toronto, Ontario, M5T1P8, Canada; Clinical Psychology & Psychotherapy Technical University Dresden, 01187, Dresden, Germany; Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University , Moscow, 119991 , Russian Federation

22. SUAL, HCL, CH Le Vinatier; Univ Lyon; UCBL; INSERM U1028; CNRS UMR5292, Centre de Recherche en Neuroscience de Lyon (CRNL) , F-69678, Bron , France

23. Bruno Scherrer Conseil, 78730, Saint Arnoult en Yvelines , France

24. Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Department of Clinical Pharmacology, CAP-TV , 13005, Marseille , France

25. Addiction Treatment Center, Local Health Unit, ASL Biella, 13875, Biella, Italy

26. Institute of Psychopharmacology, Central Institute of Mental Health, Heidelberg University , D-68159, Mannheim , Germany

27. Bethanian Hospital for Psychiatry, Psychosomatics and Psychotherapy , 17489, Greifswald , Germany

Abstract

AbstractAimsThe estimated effect of sodium oxybate (SMO) in the treatment of alcohol dependence is heterogeneous. Population severity and treatment duration have been identified as potential effect modifiers. Population severity distinguishes heavy drinking patients with <14 days of abstinence before treatment initiation (high-severity population) from other patients (mild-severity population). Treatment duration reflects the planned treatment duration. This study aimed to systematically investigate the effect of these potential effect moderators on SMO efficacy in alcohol-dependent patients.MethodsNetwork meta-regression allows for testing potential effect modifiers. It was selected to investigate the effect of the above factors on SMO efficacy defined as continuous abstinence (abstinence rate) and the percentage of days abstinent (PDA). Randomized controlled trials for alcohol dependence with at least one SMO group conducted in high-severity and mild-severity populations were assigned to a high-severity and mild-severity group of studies, respectively.ResultsEight studies (1082 patients) were retained: four in the high-severity group and four in the mild-severity group. The high-severity group was associated with larger SMO effect sizes than the mild-severity group: abstinence rate risk ratio (RR) 3.16, P = 0.004; PDA +26.9%, P < 0.001. For PDA, longer treatment duration was associated with larger SMO effect size: +11.3% per extra month, P < 0.001. In the high-severity group, SMO showed benefit: abstinence rate RR 2.91, P = 0.03; PDA +16.9%, P < 0.001. In the mild-severity group, SMO showed benefit only in PDA for longer treatment duration: +23.9%, P < 0.001.ConclusionsIn the retained studies with alcohol-dependent patients, high-severity population and longer treatment duration were associated with larger SMO effect sizes.

Funder

D&A Pharma

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/alcalc/article-pdf/58/2/125/49498698/agac070.pdf

Reference34 articles.

1. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects;Addolorato;Expert Opin Drug Saf,2020

2. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies;Brink;Alcohol Alcohol,2013

3. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study;Brink;J Psychopharmacol,2014